Media headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.4315994981647 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
- Intercept Pharmaceuticals (ICPT) PT Raised to $155.00 (americanbankingnews.com)
- Intercept Pharmaceuticals, Inc., (NASDAQ: ICPT) – Today’s Hot Stock Under Review – Stock Watch (stocksnewstimes.com)
- Intercept Pharmaceuticals Inc (ICPT) Forecasted to Earn FY2017 Earnings of ($13.17) Per Share (americanbankingnews.com)
- Cantor Fitzgerald Analysts Give Intercept Pharmaceuticals (ICPT) a $58.00 Price Target (americanbankingnews.com)
- Intercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial Results and Provides Business Update (finance.yahoo.com)
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up $2.61 during mid-day trading on Thursday, reaching $56.02. The company had a trading volume of 1,447,000 shares, compared to its average volume of 1,092,439. Intercept Pharmaceuticals has a 1 year low of $51.05 and a 1 year high of $135.59. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. The stock has a market cap of $1,490.00, a P/E ratio of -4.24 and a beta of -2.13.
Several equities analysts have weighed in on ICPT shares. Wedbush restated a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, January 5th. Deutsche Bank initiated coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $106.00 price target for the company. Goldman Sachs Group cut Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a report on Wednesday, November 1st. Five investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $132.14.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Intercept Pharmaceuticals (ICPT) Stock Price” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2018/02/15/intercept-pharmaceuticals-icpt-receives-daily-news-impact-rating-of-0-21.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.